Cargando…
Pharmacokinetics of a New Oral Vitamin D Receptor Activator (2-Methylene-19-Nor-(20S)-1α,25-Dihydroxyvitamin D(3)) in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism on Hemodialysis
BACKGROUND: 2-Methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D(3) (DP001 or 2MD) is a novel, potent 1α-hydroxylated vitamin D analog that binds to the vitamin D receptor and suppresses parathyroid hormone synthesis and secretion with potential for an improved safety profile compared to existing activ...
Autores principales: | Pandey, Richa, Zella, Julia B., Zhu, Jinge G., Plum, Lori A., Clagett-Dame, Margaret, Blaser, William J., Bedale, Wendy, DeLuca, Hector F., Coyne, Daniel W. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5694423/ https://www.ncbi.nlm.nih.gov/pubmed/28905271 http://dx.doi.org/10.1007/s40268-017-0210-z |
Ejemplares similares
-
Antibody production in mice requires neither vitamin D, nor the vitamin D receptor
por: Plum, Lori A., et al.
Publicado: (2022) -
Differential activity of 2-methylene-19-nor vitamin D analogs on growth factor gene expression in rhino mouse skin and comparison to all-trans retinoic acid
por: Ahrens, Jamie M., et al.
Publicado: (2017) -
MON-388 Total and Free 1,25dihydroxyvitamin D Levels in Postmenopausal Patients with Primary Hyperparathyroidism
por: Meng, Lingqiong, et al.
Publicado: (2020) -
Suppressive Effect of 19-nor-1α-25-Dihydroxyvitamin D2 on Gastric Cancer Cells and Peritoneal Metastasis Model
por: Park, Mi Ra, et al.
Publicado: (2012) -
1,25-Dihydroxyvitamin D and the Vitamin D Receptor Gene Polymorphism Apa1 Influence Bone Mineral Density in Primary Hyperparathyroidism
por: Christensen, Monika H. E., et al.
Publicado: (2013)